Longevity peptides on TikTok: separating signal from hype

What did @paulbakhtiar actually say?

The creator recommends three compounds for clinic anti-aging protocols: Epitalon (called "apothelen" throughout), MOTS-c (called "matzi"), and NAD+. The core claims are specific: Epitalon "extends telomeres" and extends cell life before apoptosis, MOTS-c keeps mitochondria healthy and can "heal metabolic damage over time," and NAD+ supports longevity generally. He also notes Epitalon should be used "about once or twice a year."

The mispronunciations are worth noting, not to be pedantic, but because clinics recommending these compounds to clients should be able to name them correctly. "Apothelen" and "matzi" aren't recognizable variants. If you're educating clients, vocabulary matters for informed consent.

He frames these as education tools for clinic operators, not as direct consumer advice, which is a reasonable framing. He also correctly notes NAD+ is not a peptide, which shows some baseline technical awareness.

Does the science back this up?

Partially, but the Epitalon claim is overstated in a way that matters clinically. The telomere extension evidence is real but limited to in vitro and animal models. Human longevity data does not exist yet.

Epitalon (epithalon, a tetrapeptide derived from the pineal gland peptide epithalamin) has shown telomerase activation in cell studies. Khavinson et al. (2003, Neuro Endocrinology Letters) reported telomere elongation in human somatic cells in vitro. A separate Khavinson paper (2004, Bulletin of Experimental Biology and Medicine) showed lifespan extension in fruit flies and mice. These are not trivial findings. But saying it "extends telomeres" as a general clinical fact skips over the fact that no randomized controlled human trial has confirmed this endpoint in vivo.

MOTS-c research is genuinely interesting. Lee et al. (2015, Cell Metabolism) identified it as a mitochondrial-derived peptide that regulates metabolic homeostasis and insulin sensitivity in mice. Human data remains sparse. The claim that it "heals metabolic damage over time" is ahead of the evidence.

NAD+ precursor research (NMN, NR) has more human trial data than the other two. Yoshino et al. (2021, Science) showed NMN improved muscle insulin sensitivity in postmenopausal women. But direct NAD+ IV or oral supplementation longevity claims in humans are still in early-phase territory.

What did they get wrong (or right)?

The biggest error is presenting telomere extension as an established clinical outcome. It isn't. Saying Epitalon "extends the life of those cells" before apoptosis misrepresents how telomere biology works and conflates in vitro findings with clinical reality.

Telomeres shorten with each cell division, and longer telomeres are associated with younger biological age in observational data. But the relationship is not simply linear, and longer telomeres are also associated with some cancer risks in certain tissues. A clinic telling clients Epitalon extends their cells' lives is making a causal leap the human data does not support.

What he got right: correctly identifying MOTS-c as mitochondria-focused, correctly separating NAD+ from the peptide category, and correctly noting Epitalon is not a frequent-use compound. The dosing frequency comment aligns with how compounding pharmacies and practitioners currently approach Epitalon protocols, though no FDA-approved dosing guidance exists.

He also deserves credit for framing this as client education rather than promising outcomes. That's the right posture for clinic operators working in a regulatory gray zone.

What should you actually know?

None of these three compounds are FDA-approved for anti-aging, longevity, or telomere extension. Epitalon and MOTS-c are available through compounding pharmacies in the U.S. under current regulatory frameworks, but that status is subject to change. NAD+ infusions and precursors exist in a separate regulatory category.

For clinic operators, the compliance risk here is real. Marketing Epitalon as a telomere extender or MOTS-c as a metabolic repair agent to consumers could attract FTC or state medical board scrutiny, depending on how those claims are made in writing. The video's framing as "education" provides some distance, but clinics operationalizing these talking points in intake materials or websites should be careful.

The underlying science on all three compounds is worth watching. Epitalon in particular has a longer research trail than most peptides in this category, primarily from Russian gerontology research. The evidence base is thin by Western RCT standards but not zero. Dismissing it entirely is as lazy as overstating it.

• Epitalon: interesting preclinical data, no confirmed human longevity trials
• MOTS-c: compelling mechanism, mostly rodent data as of 2024
• NAD+ precursors: the strongest human evidence of the three, still not conclusive for longevity endpoints